Roivant's Stomach Drug Sale to Roche: A $7 Billion Deal in the Works
Biotech company Roivant Sciences, founded by Republican presidential candidate Vivek Ramaswamy, is in discussions to sell an experimental drug for a debilitating stomach disease to Roche Holding in a deal that could be worth over $7 billion. The drug is intended for the treatment of ulcerative colitis and Crohn's disease, which affects up to two million people in the United States.